Addressing Central Nervous System (CNS) Disorders

Redefining the Treatment Paradigm

About Glauser Life Sciences, Inc.

Glauser Life Sciences, Inc. is developing what we believe to be next-generation, revolutionary treatments for Central Nervous System (CNS) disorders of various types. Working with a talented team of expert scientists, doctors and business leaders, we're pioneering research and development which we hope will redefine the paradigm of treatment, and lead to products that help those in need.


Meet the Team

team member
Christopher Adams
CEO / Founder

Christopher is a private equity investor, team builder and founder of several successful startups, including Qooco.com, an educational technology company that empowers children and adults to learn spoken english via computer, tablet and mobile phones as well as train hospitality employees in a variety of hotel skills and languages. Christopher founded Glauser Life Sciences, the maker of Levium, to help people suffering from various central nervous system disorders, including anxiety. Having experienced the effects of general anxiety disorder himself, and most recently with his daughter, Christopher saw the need for an effective and all-natural anxiety solution without the dangerous side effects of pharmaceuticals. Levium is the embodiment of this vision. Christopher holds a B.A. from the University of Arizona.

team member
Don Cadora
Marketing & Community Manager

Don Cadora has directed marketing efforts for diverse brands and verticals through top advertising agencies, social media marketing firms, and digital agencies (Goodby, Silverstein & Partners, Resonate Social, Lexim Global). Cadora runs his own Los Angeles marketing consultancy firm and continues to develop and implement integrated digital marketing and sales strategies with clients in entertainment, fashion, finance, and health.

team member
Dr. David Kipper M.D.
Clinical Director

Dr. Kipper has practiced internal medicine in Beverly Hills for three decades and co-founded the Medical Group of Beverly Hills in 1987, which is the largest multispecialty group in the community. Dr. Kipper is a member of the California Society of Addiction Medicine and the American Society of Addiction Medicine. Dr. Kipper hosts a weekly interactive radio program on KABC. He has published numerous articles on health and health care policy and has been asked to appear as an expert commentator on all major networks on issues relating to internal medicine, addiction, and health care. He attended medical school at the University of California at Los Angeles.

team member
Dr. Nicolas Gilpin
Research Advisor

Dr. Gilpin is currently an Associate Professor at Louisiana State University Health Sciences Center in New Orleans, LA and the Principal Investigator at the Gilpin Lab, Neurobiology of Stress and Addiction. His research career has focused on examining the role of neuropeptides in addiction disorders and related mental health disorders. His research uses pre-clinical models to study circuit, cellular, and molecular processes associated with addiction. Dr. Gilpin is the recipient of the Presidential Early Career Awards for Scientists and Engineers awarded by President Obama on January 9, 2017. Dr. Gilpin received his Ph.D. in Psychobiology from Purdue University and completed a post-doctoral fellowship at The Scripps Research Institute in La Jolla, CA.

team member
Dr. Todd Thiele
Research Advisor

Dr. Thiele’s research training focuses on the brain mechanisms that underlie ingestive behaviors such as alcohol and food intake. In 2001 he joined the Department of Psychology and Neuroscience at the University of North Carolina at Chapel Hill (UNC-CH), where he is currently a tenured professor and the Director of the Behavioral Neuroscience Program. Dr. Thiele is a leading expert on the role of stress- and feeding-related neuropeptides with over 20 years of pre-clinical research experience on this topic and over 85 peer-reviewed papers in leading science journals. Dr. Thiele’s research has provided important insights into the central mechanisms of neuropeptide Y, a stress “reducing” neuropeptide, and corticotropin releasing factor, a stress “inducing” neuropeptide. He received his Ph.D. in Psychology from Kansas State University and holds a B.S. from the University of Wisconsin-Madison.


We Want To Hear From You!

Do you have an interest in Glauser Life Sciences, Inc?
Please use the form below to reach out to us.